WO2012011707A3 - Substituted pyridinone derivatives and methods for manufacturing the same - Google Patents

Substituted pyridinone derivatives and methods for manufacturing the same Download PDF

Info

Publication number
WO2012011707A3
WO2012011707A3 PCT/KR2011/005268 KR2011005268W WO2012011707A3 WO 2012011707 A3 WO2012011707 A3 WO 2012011707A3 KR 2011005268 W KR2011005268 W KR 2011005268W WO 2012011707 A3 WO2012011707 A3 WO 2012011707A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes mellitus
compound
same
diseases
manufacturing
Prior art date
Application number
PCT/KR2011/005268
Other languages
French (fr)
Other versions
WO2012011707A2 (en
Inventor
Yong Kyu Park
Sung Hun Bang
Jin Woong Kim
Han Kyu Lee
Jae Hyun Kim
Chang Mo Son
Jun Hee Lee
Chang Yong Shin
Jong Chan Lee
Jae Keol Rhee
Original Assignee
Hyundai Pharm Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyundai Pharm Co., Ltd. filed Critical Hyundai Pharm Co., Ltd.
Publication of WO2012011707A2 publication Critical patent/WO2012011707A2/en
Publication of WO2012011707A3 publication Critical patent/WO2012011707A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Disclosed are a novel compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and the compound-containing pharmaceutical composition for treating a metabolic disorder. Specifically, the disclosed compound is represented by [Formula 1]. The compound activates GPR119, and thus can be used for treating metabolic disorders, that is, diabetes mellitus, diabetes mellitus-related diseases, diabetes mellitus-related microvessel complications, diabetes mellitus-related large vessel complications, cardiovascular disorders, metabolic syndrome and its constituent diseases, obesity, and other diseases. In Formula 1, P1, P2, P3, P4, L1, R4, n4, X, Y, Z1 and Z2 are the same as defined above.
PCT/KR2011/005268 2010-07-23 2011-07-18 Substituted pyridinone derivatives and methods for manufacturing the same WO2012011707A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100071674A KR20120011357A (en) 2010-07-23 2010-07-23 Substituted pyridinone derivatives and methods for manufacturing the same
KR10-2010-0071674 2010-07-23

Publications (2)

Publication Number Publication Date
WO2012011707A2 WO2012011707A2 (en) 2012-01-26
WO2012011707A3 true WO2012011707A3 (en) 2012-05-31

Family

ID=45497277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/005268 WO2012011707A2 (en) 2010-07-23 2011-07-18 Substituted pyridinone derivatives and methods for manufacturing the same

Country Status (2)

Country Link
KR (1) KR20120011357A (en)
WO (1) WO2012011707A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031618B1 (en) 2011-06-09 2019-01-31 Ризен Фармасьютикалз Са Compounds as modulators of gpr-119
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2014052619A1 (en) * 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
ES2663806T3 (en) 2013-12-19 2018-04-17 unshine Lake Pharma Co., Ltd. Heterocyclic nitrogen derivatives and their application in the treatment of tissue fibrosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090018055A1 (en) * 2007-05-04 2009-01-15 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
US20090286812A1 (en) * 2008-05-19 2009-11-19 Shawn David Erickson GPR119 Receptor Agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090018055A1 (en) * 2007-05-04 2009-01-15 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
US20090286812A1 (en) * 2008-05-19 2009-11-19 Shawn David Erickson GPR119 Receptor Agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HA OVERTON ET AL.: "GPR119, a novel G protein receptor target for the treatment of type 2 diabetes and obesity", BRITISH JOURNAL OF PHARMACOLOGY, vol. 153, 2008, pages S76 - S81, XP002544526, DOI: doi:10.1038/sj.bjp.0707529 *

Also Published As

Publication number Publication date
WO2012011707A2 (en) 2012-01-26
KR20120011357A (en) 2012-02-08

Similar Documents

Publication Publication Date Title
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2007106469A3 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
IL193951A (en) Bridged compound with central pyrrolidine units, an intermediate compound for the preparation of the bridged compound, a process for producing the bridged compound, use of the bridged compound for the manufacture of a medicament, a pharmaceutical composition, a method of preparing a pharmaceutical composition and a method for the preparation of a pharmaceutically acceptable salt of a non-salt compound
WO2012011707A3 (en) Substituted pyridinone derivatives and methods for manufacturing the same
IL210577A (en) Substituted 1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl acetic acid compound, salt, hydrate and solvate thereof, a pharmaceutical composition, the compound, salt, hydrate, solvate or pharmaceutical composition for use as a medicament or for use in a method of treatment, use of the compound, salt, hydrate, solvate, or pharmaceutical composition in the manufacture of a medicament and a process for preparing a composition
WO2012122340A8 (en) Soluble guanylate cyclase activators
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2013087716A3 (en) Fgfr antibody drug conjugates (adcs) and the use thereof
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
IL194871A (en) Iap bir domain binding compound, an intermediate compound, process for producing the compound, method for preparation of a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it and use of the compound for the manufacture of a medicament
HK1164292A1 (en) Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2008130312A8 (en) A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1h-indole-5-carbonitrile 701
WO2009117150A3 (en) Method of treating lupus with ceramide derivatives
WO2007087204A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
WO2012099942A3 (en) Methods and compositions for treating metabolic syndrome
WO2011085643A8 (en) Fused pyridine derivatives
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
GEP20115342B (en) New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them
EP2149379A4 (en) Use of a vegetable drug composition in the manufacturing of a pharmaceutical preparation for the treatment of portal hypertension caused by hepatocirrhosis
WO2010011811A3 (en) 3-(phenoxyphenylmethyl)pyrrolidine compounds
WO2010070677A3 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
WO2008098978A3 (en) Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11809834

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11809834

Country of ref document: EP

Kind code of ref document: A2